Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA -0.56%51 EV-to-EBIT is 136.80 as of Sep. 02, 2026, which is 222% above its 10-year median of 42.46. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 51/100 and a GF Value™ of ₹191.31 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 683 Drug Manufacturers companies, Piramal Pharma ranks worse than 95.61% on this metric.
The historical rank and industry rank for Piramal Pharma's EV-to-EBIT or its related term are showing as below:
NSE:PPLPHARMA'
s EV-to-EBIT Range Over the Past 10 Years
Min: 23.12 Med: 42.46 Max: 163.82
Current: 136.79
During the past 6 years, the highest EV-to-EBIT of Piramal Pharma was 163.82. The lowest was 23.12. And the median was 42.46.
NSE:PPLPHARMA's EV-to-EBIT is ranked worse than 95.61% of 683
companies
in the Drug Manufacturers industry
Industry Median: 16.09
vs NSE:PPLPHARMA: 136.79
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Piramal Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was ₹223,029 Mil.
Piramal Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,382 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma EV-to-EBIT Related Terms
Piramal Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's EV-to-EBIT falls into.
Piramal Pharma's current Enterprise Value is ₹325,891 Mil.
Piramal Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,382 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a EV-to-EBIT of 136.80 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Piramal Pharma and its competitors. This is 222% above median its historical median of 42.46. Over the past decade, Piramal Pharma's EV-to-EBIT has ranged from 23.12 to 163.82. According to the industry distribution chart, Piramal Pharma ranks #653 out of 683 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Piramal Pharma's EV-to-EBIT too high?
Piramal Pharma's current EV-to-EBIT of 136.80 is 222% above median its 10-year median of 42.46. Over the past 10 years, this metric has ranged from a low of 23.12 to a high of 163.82. The Drug Manufacturers industry median EV-to-EBIT is 16.09. Piramal Pharma's value of 136.80 is 750.2% above this industry median. Based on the distribution chart, Piramal Pharma ranks #653 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #653 out of 683 companies for EV-to-EBIT. This places Piramal Pharma in the lower half of its industry. The industry median EV-to-EBIT is 16.09. Piramal Pharma's value of 136.80 is 750.2% above this benchmark. Historically, Piramal Pharma's own EV-to-EBIT has ranged from 23.12 to 163.82 over the past decade. While the company's 10-year median is 42.46 vs. the industry median of 16.09, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.09, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current EV-to-EBIT of 136.80 is 750.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current EV-to-EBIT is 136.80, which is 222% above median its own 10-year median of 42.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹191.31, compared to a current price of ₹213.20 — trading 11.4% above its estimated fair value. The current EV-to-EBIT is 136.80, which is 222% above median its 10-year median of 42.46 and 750.2% above the Drug Manufacturers industry median of 16.09. Piramal Pharma's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current EV-to-EBIT is 136.80 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹213.20 is trading 11.4% above its estimated GF Value™ of ₹191.31.
GuruFocus considers Piramal Pharma to be Modestly Overvalued.
Key valuation signals for NSE:PPLPHARMA:
EV-to-EBIT: 136.80 (222% above median its 10-year median of 42.46)
GF Value™: ₹191.31 vs. price of ₹213.20 (11.4% above fair value)
Industry Position: 750.2% above the Drug Manufacturers median (#653 of 683)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score
Get the complete analysis for NSE:PPLPHARMA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
